Spondyloarthritis & psoriatic arthritis
Does a short course of etanercept influence disease progression and radiographic changes in patients suspected of non-radiographic axial spondyloarthritis? Three -years follow- up of a placebo-controlled trial
Authors' conclusion
A short course of etanercept in patients with suspected nr-axSpA did not affect disease activity, the chance of biological treatment, or radiographic progression after 3 years of follow-up.
Study context
- Population
- Patients with inflammatory back pain and suspected non-radiographic axial spondyloarthritis (nr-axSpA), Bath Ankylosing Disease Activity Index (BASDAI) ≥ 4
- Participants
- 80 patients
- Comparison
- Etanercept 25 mg twice weekly for 16 weeks vs placebo
- Etanerceptn = 40
- Placebon = 40reference
- Primary endpoint
- Long-term disease activity (BASDAI, ASDAS) and radiographic changes (modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), Bath Ankylosing Spondylitis Radiology Index (BASRI))
- Follow-up
- Up to 3 years
Methodological detailsplacebo-controlled, 3-year follow-up, Followed without treatment restrictions after 24 weeks, for up to 3 years
- Placebo-controlled
- 3-year follow-up
- Followed without treatment restrictions after 24 weeks, for up to 3 years
Primary result
As reported in the abstract
BASDAI, mean difference between initial randomisation groups
0.9
95% CI −1.1;0.7p = 0.6
Ankylosing Spondylitis Disease Activity Score (ASDAS), mean between initial randomisation groups
0.3
95% CI 0.6;3.1p = 0.5
Further findings
Radiographic changes of sacroiliac joints or spine · up to 3 years
- No differences between the two groups
Bath Ankylosing Spondylitis Metrology Index (BASMI) and function scores · up to 3 years
- Remained stable over 3 years
Diagnosis at follow-up and biological treatment · up to 3 years
- Diagnosed with SpA, predominantly axSpA
- 84%
- Biological treatment started after 24 weeks
- 30%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →